
Xu HH et al: MRTF-A epigenetically regulates renal fibrosis in diabetic nephropathy

Supplemental material Supplemental figures: 15 Supplemental table: 1







Fig.S1: Wild type (WT) or MRTF-A deficient (KO) mice were fed with a high-fat diet (HFD) or a control diet (AL) for 16 weeks. (**A**) Body weight was measured before the mice were sacrificed for histology. N=5-10 mice for each group. (**B**, **C**) Glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed as described under *Methods*. N=3-6 mice for each group (**D**) Expression of Col4a1 was assessed by qPCR. N=4 mice for each group. (**E**) Paraffin-embedded kidney sections were stained with periodic acid-Schiff (PAS). Mesangial index was calculated by dividing PAS-positive area by total glomerular area. N=4 mice for each group (**F**) Immunohistochemistry was performed with anti-CD3, anti-F4/80, or anti-CD45. N=4 mice for each group. (**G**) Immunohistochemistry was performed with anti-collagen type I. N=4 mice for each group.






Fig.S2: Wild type (WT) or MRTF-A deficient (KO) mice were injected with STZ or vehicle (Vec) and sacrificed after 16 weeks. (**A**) ITT was performed as described under *Methods*. N=3-5 mice for each group (**B**) Urinary albumin excretion was measured as described under *Methods*. N=3-5 mice for each group. (**C**) Expression of Col4a1 was assessed by qPCR. N=4 mice for each group. (**D**) Paraffin-embedded kidney sections were stained with periodic acid-Schiff (PAS). (**E**) Immunohistochemistry was performed with anti-CD3, anti-F4/80, or anti-CD45. N=3-6 mice for each group. (**F**, **G**) Renal fibrosis was evaluated by picrosirius red and Masson's trichrome stainings and quantified by Image Pro. N=3 mice for each group. (**H**) Immunohistochemistry was performed with anti-collagen type I. N=3 mice for each group. (**I**) Expression of type I collagen in the kidneys was examined by qPCR. N=5 mice for each group.




Fig.S3: (A) Collagen promoter luciferase constructs were transfected into HK-2 cells with or without MRTF-A followed by treatment with glucose. Data are expressed as relative luciferase unit (RLU). (B) Collagen promoter luciferase constructs were transfected into wild type (WT) or MRTF-A deficient (KO) MEF cells followed by treatment with glucose. Data are expressed as relative luciferase unit (RLU). N.S., no statistical significance (C) NRK-52E was transfected with MRTF-A siRNA or scrambled siRNA. MRTF-A expression was measured by qPCR and Western.

		Fold Change (comparing to control group) Group 1		
Position	Symbol	Fold Change	Comments	
A01 A02	Acta2 Agt	0.2864 3.8593	OKAY B	
N03 N04	Akt1 Bcl2	1.5762 0.9816	OKAY OKAY	
\ 05	Bmp7	1.2669	OKAY	
06 07	Cav1 Ccl11	0.8633 2.6656	OKAY B	
·08	Ccl12	1.8431	OKAY	
\09 \10	Ccr2	1.4774 6.6572	OKAY A	
\11	Cebpb	3.0664	OKAY	
N12 301	Col1a2 Col3a1	0.4331 0.2618	OKAY OKAY	
302	Ctgf	0.8564	OKAY	
303 304	Cxcr4 Dcn	0.8786 0.6535	OKAY OKAY	
305	Edn1	0.6886	OKAY	
306 307	Egf Eng	1.6027 0.4585	A OKAY	
808	Fasi	0.4383	C	
809	Grem1	1.2652	OKAY	
310 311	Hgf Ifng	2.5321 0.2199	OKAY B	
112	II10	0.1087	В	
001	II13 II13ra2	5.326 0.4202	B B	-
203	II1a	1.4942	OKAY	
004 005	II1b II4	3.2264 0.3217	OKAY B	-
206	II5	0.8752	В	
07 08	llk Inhbe	0.8369 0.3868	OKAY B	
009	Itga1	1.0664	OKAY	
C10	ltga2	0.8484	OKAY	
011	Itga3 Itgav	1.3354 1.1209	OKAY OKAY	-
01	ltgb1	1.1793	OKAY	
002	ltgb3 ltgb5	0.8077 1.4687	OKAY OKAY	-
004	Itgb6	1.1381	OKAY	
005	ltgb8 Jun	1.4247 1.3419	OKAY OKAY	-
007	Lox	0.5164	OKAY	
008	Ltbp1 Mmp13	0.7853 1.5288	OKAY OKAY	
010	Mmp14	1.2718	OKAY	
011	Mmp1a	2.5493	OKAY	
012	Mmp2 Mmp3	1.6445 0.4699	OKAY A	-
02	Mmp8	0.3823	OKAY	
03	Mmp9 Myc	0.5309 0.9717	OKAY OKAY	
05	Nfkb1	1.2248	OKAY	
06 07	Pdgfa Pdgfb	0.7345 1.1305	OKAY OKAY	
-08	Plat	1.376	OKAY	
E09 E10	Plau	1.6146 0.9634	OKAY C	
11	Plg Serpina1a	0.9634	C	
12	Serpine1	1.0722	OKAY	
-01 -02	Serpinh1 Smad2	1.2828 1.2608	OKAY OKAY	-
-03	Smad3	1.6185	OKAY	
-04 -05	Smad4 Smad6	1.1698	OKAY OKAY	
-06	Smad7	1.5073	OKAY	
07 08	Snai1 Sp1	1.6818 1.4902	B OKAY	
-09	Stat1	1.7463	OKAY	
10	Stat6	1.3604 1.7116	OKAY	
11	Tgfb1 Tgfb2	1.7110	OKAY OKAY	 -
301	Tgfb3	1.1346	OKAY	
302 303	Tgfbr1 Tgfbr2	1.502 1.5594	OKAY OKAY	-
304	Tgif1	0.9524	OKAY	
305 306	Thbs1 Thbs2	1.2435 1.13	OKAY OKAY	_
307	Timp1	0.3729	OKAY	
308 309	Timp2	0.641 0.9255	OKAY	
310	Timp3 Timp4	0.9634	OKAY C	
311	Tnf Vogfa	1.9686	OKAY	-
612 101	Vegfa Actb	0.9916 1.0929	OKAY	-
102	B2m	0.893	OKAY	
103 104	Gapdh Gusb	1.4623 1.0247	OKAY OKAY	-
105	Hsp90ab1	1.1973	OKAY	
106 107	MGDC RTC	0.9634 1.0292	C OKAY	-
H08	RTC	1.0745	OKAY	
109 110	RTC PPC	1.1236 0.8813	OKAY OKAY	
111	PPC	0.874	OKAY	
112	PPC	0.9256	OKAY	
nd is reas hese data the othe nd reporte his fold-cl	ne's average onably low in mean that r sample sug ed fold-chang nange result	threshold cycle is relatively high (> 30) in either the cont the other sample (< 30). the gene!!! expression is relatively low in one sample an goesting that the actual fold-change value is at least as I pe result. The sample of the sample and t	d reasonably detected arge as the calculated afore, it is important to	
evel is low r relatively his fold-cl	, in both cor high (p > 0. nange result	threshold cycle is relatively high (> 30), meaning that trol and test samples, and the p-value for the fold-chang 05). may also have greater variations; therefore, it is importa- plicates to validate the result for this gene.	e is either unavailable	
alue (defa	ault 35), in I	e threshold cycle is either not determined or greater th both samples meaning that its expression was undetec s and un-interpretable.		

Fig.S4: Identification of novel MRTF-A target genes by PCR array. Mouse fibrosis PCR array was performed as described under *Methods* with RNA prepared from MRTF-A deficient renal tubular epithelial cells treated with high glucose (Group 1) or wild type RTEs treated with high glucose (control group).




Fig.S5: Validation of MRTF-A target genes *in vivo* and *in vitro*. (**A**) Wild type (WT) or MRTF-A deficient (KO) mice were induced to develop diabetic nephropathy by high-fat diet (HFD). Expression of *Col1a3*, *Acta2*, and *Timp1* in the kidneys was examined by qPCR. N=5 mice for each group. (**B**) Wild type (WT) or MRTF-A deficient (KO) mice were induced to develop diabetic nephropathy by STZ injection. Expression of *Col1a3*, *Acta2*, and *Timp1* in the kidneys was examined by qPCR. N=5 mice for each group. (**C**) NRK-52E cells were transfected with indicated siRNAs followed by treatment with glucose. Expression of *Col1a3*, *Acta2*, and *Timp1* in the kidneys was examined by qPCR.




Fig.S6: Direct binding of MRTF-A to new target genes *in vivo* and *in vitro*. (**A**) Wild type (WT) or MRTF-A deficient (KO) mice were induced to develop diabetic nephropathy by high-fat diet (HFD). ChIP assays were performed using kidney lysates with anti-MRTF-A. SBE, Smad-binding element; SRE, serum response element/CArG box. N=3 mice for each group. (**B**) Wild type (WT) or MRTF-A deficient (KO) mice were induced to develop diabetic nephropathy by STZ injection. ChIP assays were performed using kidney lysates with anti-MRTF-A. N=3 mice for each group. (**C**) NRK-52E cells were treated with glucose or mannitol for 24 hours. ChIP assays were performed using kidney lysates with anti-MRTF-A.





Fig.S7: (**A, B**) NRK-52E cells were treated with glucose of indicated concentrations for 24 hours. Expression of MRTF-A was measured by qPCR (A) and Western (B). (**C**) A MRTF-A promoter-luciferase fusion construct was transfected into NRK-52E cells followed by treatment with glucose or mannitol.






Fig.S8: (**A**) NRK-52E cells were treated with glucose (35mM) in the presence or absence of 17β-estradiol (10^{-7} - 10^{-9} M) for 24 hours. Expression of MRTF-A was measured by qPCR. (**B**) NRK-52E cells were treated with glucose (35mM) in the presence or absence of 17β-estradiol (10^{-7} - 10^{-9} M) for 24 hours. ChIP assays were performed with anti-MRTF-A.




Fig.S9: (**A-D**) WT or KO mice were induced to develop diabetic nephropathy by HFD. ChIP assays were performed using kidney lysates with anti-H3K9 (A), anti-H3K18 (B), anti-H3K27 (C), and anti-H3K4Me3 (D). N=3 mice for each group




Fig.S10: (A-C) WT or KO mice were induced to develop diabetic nephropathy by STZ injection. ChIP assays were performed using kidney lysates with anti-H3K18 (A), anti-H3K27 (B), and anti-H3K4Me3 (C). N=3 mice for each group




Fig.S11: (**A-C**) WT or KO mice were induced to develop diabetic nephropathy by HFD. ChIP assays were performed using kidney lysates with anti-H3K18 (A), anti-H3K27 (B), and anti-H3K4Me3 (C). N=3 mice for each group




Fig.S12: (**A-C**) WT or KO mice were induced to develop diabetic nephropathy by STZ injection. ChIP assays were performed using kidney lysates with anti-H3K18 (A), anti-H3K27 (B), and anti-H3K4Me3 (C). N=3 mice for each group





Fig.S13: (**A**) Primary renal tubular epithelial cells were isolated from WT or KO mice and treated with glucose. ChIP assays were performed with anti-p300. (**B**) Collagen promoter luciferase constructs were transfected into NRK-52E cells with indicated expression constructs. (**C**) NRK-52E was transfected with p300 siRNA or scrambled siRNA. p300 expression was measured by qPCR and Western. (**D**) Collagen promoter luciferase constructs were transfected into NRK-52E cells with indicated expression constructs and siRNAs.






Fig.S14: (**A**) Primary renal tubular epithelial cells were isolated from WT or KO mice and treated with glucose. ChIP assays were performed with anti-p300. (**B**) NRK-52E was transfected with WDR5 siRNA or scrambled siRNA. WDR5 expression was measured by qPCR and Western.




Fig.S15: (**A**) Primary renal tubular epithelial cells were isolated from WT or KO mice and treated with glucose or mannitol. Re-ChIP assays were performed with indicated antibodies. (**B**) NRK-52E cells were treated with glucose (35mM) in the presence or absence of 17β -estradiol (10^{-7} M) for 24 hours. Re-ChIP assays were performed with indicated antibodies.

Table I: ChIP Real-time qPCR primers

Gene name	Primer sequences		
Mouse Col1a1	Forward: 5'- ATTTGAAGTCCCAGAAAG -3'		
	Reverse: 5'- AGAAACTCCCGTCTGCTC -3'		
Mouse Col1a2	Forward: 5'-CTTCGTGCATGACTTCAGCTTT-3'		
	Reverse: 5'-CGTCCTTTAGCATGGCAAGAC-3'		
Mouse Col1a3 #1	Forward: 5'- GACTCTGGCAAAACTCAAAGTATCA-3'		
	Reverse: 5'- TAGGAATGTGCTTTGTGATAGCCT -3'		
Mouse Col1a3 #2	Forward: 5'- AGACCTTCATTCCCAGCTACTTG-3'		
	Reverse: 5'- CTCTCTACCACTGACCTGCATCTC -3'		
Mouse Acta2	Forward: 5'-AGCAGAACAGAGGAATGCAGTGGA AGA GAC-3'		
	Reverse: 5'-CCTCCCACTCGCCTC CCA AACAAGGAGC-3'		
Mouse Timp1 #1	Forward: 5'- AGGACTGTGCATGACGTGGAG-3'		
	Reverse: 5'- ACAGTGGAGAATAAATGTCCATGC -3'		
Mouse Timp1 #2	Forward: 5'- TGTGGTCAAGCAAAGCATCTG-3'		
	Reverse: 5'- TGGGTTTGTAGCTCAATTGTGC -3'		
Rat Col1a1	Forward: 5'- ATCCTTCTGATTTGAGGTC -3'		
	Reverse: 5'- AGGTGAAACTCCCGTCTG -3'		
Rat Col1a2	Forward: 5'-GACATGCTCAAGTGCTGAGTCAC-3'		
	Reverse: 5'-AGATTGCACAATGTGACGTCG-3'		
Rat Col3a1	Forward: 5'- ATCCTTCTGATTTGAGGTC -3'		
	Reverse: 5'- AGGTGAAACTCCCGTCTG -3'		
Rat Timp1	Forward: 5'-CTCTGCCACCCTCACCA-3'		
	Reverse: 5'-GGACTGGATGGGCCTCGT-3'		
Rat Acta2	Forward: 5'- CATGCACGTGGACTGTACCT -3'		
	Reverse: 5'- AAAGATGCTTGGGTCACCTG -3'		
Rat Gapdh	Forward: 5'- ATCACTGCCACCCAGAAGACTGTGGA -3'		
	Reverse: 5'-C TCATACCAGGAAATGAGCTTGACAAA -3'		